The Clinical Impact of Adverse Event Reporting
The Food and Drug Administration (FDA)'s monitoring of the continued safety of marketed
medical products depends greatly upon reporting of adverse events by health professionals. An
understanding of how FDA uses this information, and of the limitations/strengths of the national
postmarketing surveillance system, underscores the importance of this professional responsibility
to the public health.
A MEDWATCH Continuing Education Article
Table of Contents